Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Patrick G. Enright sold 351 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $148.40, for a total transaction of $52,088.40. Following the completion of the transaction, the director now directly owns 1,717 shares in the company, valued at approximately $254,802.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jazz Pharmaceuticals PLC (JAZZ) opened at 146.09 on Tuesday. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75. The stock has a market capitalization of $8.77 billion, a price-to-earnings ratio of 22.50 and a beta of 1.10. The stock’s 50 day moving average is $152.07 and its 200 day moving average is $148.41.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. During the same quarter last year, the firm posted $2.67 EPS. The company’s revenue was up 3.5% compared to the same quarter last year. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post $10.88 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Director Patrick G. Enright Sells 351 Shares of Stock” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/29/jazz-pharmaceuticals-plc-jazz-director-patrick-g-enright-sells-351-shares-of-stock.html.

A number of research analysts have recently issued reports on JAZZ shares. HC Wainwright initiated coverage on shares of Jazz Pharmaceuticals PLC in a research report on Friday. They issued a “neutral” rating and a $144.00 price objective on the stock. Cowen and Company reiterated an “outperform” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, June 7th. BidaskClub upgraded shares of Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Royal Bank Of Canada set a $210.00 target price on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Tuesday, June 27th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $182.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, June 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. Jazz Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $180.96.

Several hedge funds have recently made changes to their positions in the stock. Toronto Dominion Bank raised its stake in shares of Jazz Pharmaceuticals PLC by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 81 shares during the period. US Bancorp DE raised its stake in shares of Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 368 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 295 shares during the period. World Asset Management Inc purchased a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at $205,000. Finally, Gargoyle Investment Advisor L.L.C. purchased a new stake in shares of Jazz Pharmaceuticals PLC during the second quarter valued at $206,000. Institutional investors and hedge funds own 88.24% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.